Novavax
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Novavax sits in the top decile of US sponsors by registered trial count (#526 of 15,742 sponsors by registered trial count).
Novavax: 31 sponsored US clinical trials, none currently recruiting.
Novavax sponsors 31 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 27 completed. 10 of these trials are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is COVID-19, with 4 trials.
Top-decile sponsor footprint
Novavax ranks in the top decile of sponsors by registered trial count (#526 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
27 of 28 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (96.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
31 total, page 1 of 1
Efficacy and Safety of NVX-CoV2705
NCT07086222
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
NCT06633835
Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years
NCT05468736
A Strain Change Study for SARS-CoV-2 rS Vaccines
NCT06409663
Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines
NCT05925127
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
NCT05975060
Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines
NCT05973006
Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines
NCT05875701
Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults
NCT05463068
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
NCT04611802
Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant
NCT04368988
Phase 3 Pivotal Trial of NanoFlu™ in Older Adults
NCT04120194
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
NCT03658629
Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)
NCT03293498
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
NCT02624947
A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults
NCT02608502
Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.
NCT02593071
Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults
NCT02307851
Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults
NCT02266628
RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.
NCT02247726
A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant
NCT02078674
RSV F Dose-Ranging Study in Women
NCT01960686
RSV-F Vaccine Dose Ranging Study in Young Women
NCT01704365
RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly
NCT01709019
A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2
NCT01596725
A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1
NCT01594320
Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine
NCT01290419
Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Older Adults
NCT01014806
Trial to Evaluate Safety and Immunogenicity of Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant)
NCT00903552
Evaluate the Safety and Immunogenicity of a Seasonal Influenza VLP Vaccine (Recombinant) in Healthy Adults
NCT00754455
Safety, Reactogenicity and Immunogenicity of an H5N1 VLP
NCT00519389
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 13 |
| Phase 3 | 8 |
| Phase 4 | 2 |
How the Novavax early-phase archive is shaped
31 indexed studies, none listed as recruiting (0% open); 27 completed (87%).
Phase mix: 10 late (III/IV) vs 21 early (I/II) (early-phase heavy).
Top condition: COVID-19 (4 trials), 6 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Novavax: archived-pipeline peers nationwide
Peers matched on 31 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Novavax sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 31 archived trials
- Children's Hospitals and Clinics of Minnesota · 31 trials · 10% recruiting
- Cook Group Incorporated · 31 trials · 0% recruiting
- Cytokinetics · 31 trials · 10% recruiting
- Halozyme Therapeutics · 31 trials · 3% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Novavax page
31 registered trials is a research-attention snapshot, not an endorsement of Novavax or any single study.
- None of Novavax's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- COVID-19 is the condition Novavax studies most, compare against other sponsors active in the same condition before evaluating a specific study. See COVID-19 trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Novavax pipeline card: 31 registered trials from official public datasets.Report a data error.